Physicochemical Properties
| Molecular Formula | C21H18N2O3S |
| Molecular Weight | 378.446 |
| Exact Mass | 378.103 |
| Elemental Analysis | C, 66.65; H, 4.79; N, 7.40; O, 12.68; S, 8.47 |
| CAS # | 351353-48-5 |
| PubChem CID | 1131802 |
| Appearance | Off-white to gray solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 608.3±55.0 °C at 760 mmHg |
| Flash Point | 321.7±31.5 °C |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.645 |
| LogP | 6.05 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 27 |
| Complexity | 462 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S1C=CC=C1C1=C(C2C=CC=CC=2)N=C(C2C=C(C(=C(C=2)OC)O)OC)N1 |
| InChi Key | JMXVHYPSBANVAQ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C21H18N2O3S/c1-25-15-11-14(12-16(26-2)20(15)24)21-22-18(13-7-4-3-5-8-13)19(23-21)17-9-6-10-27-17/h3-12,24H,1-2H3,(H,22,23) |
| Chemical Name | 2,6-Dimethoxy-4-[4-phenyl-5-(2-thienyl)-1H-imidazol-2-yl]phenol |
| Synonyms | DPTIP |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In astrocytes, DPTIP decreases exosome release by 50% at 30 μM and inhibits EV secretion in a dose-dependent manner (0.03-30 μM) [2]. |
| ln Vivo | DPTIP potently (10 mg/kg IP) inhibits IL-1β-induced astrocyte-derived EV release [1]. |
| Animal Protocol |
Animal/Disease Models: Mouse[1]. Doses: 10 mg/kg. Route of Administration: IL-1β was injected intraperitoneally (ip) (ip) 0.5 hrs (hrs (hours)) before striatal injection. Experimental Results: Brain concentrations of DPTIP were higher than its IC50 for nSMase2 inhibition at least 4 hrs (hrs (hours)) after compound administration. The number of astrocyte-derived EVs was diminished by 51 ± 13% 2 hrs (hrs (hours)) after IL-1β administration. |
| References |
[1]. DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. Sci Rep. 2018 Dec 7;8(1):17715. [2]. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~660.61 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.50 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6424 mL | 13.2118 mL | 26.4236 mL | |
| 5 mM | 0.5285 mL | 2.6424 mL | 5.2847 mL | |
| 10 mM | 0.2642 mL | 1.3212 mL | 2.6424 mL |